Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
This cost-effective tool will be of immense benefit to other high burden countries as well.
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
RNAstorm and DNAstorm RNA/DNA extraction kits will be sold exclusively through the Biotium website and authorized distributors
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
The EBUS is designed to support the diagnosis and staging of various lung disorders
Formula attenuates 99% of 365 coronaviruses in computer models
Subscribe To Our Newsletter & Stay Updated
